Clinical analysis of 66 patients of retinoblastoma_Chinese Journal of Ocular Fundus Diseases

Authors：

Zhou Sirui , Min Xiaoxue , Tao Yunhan , Mu Jia , Gou Yueqin , Tao Mengying ,  Zhang Ming

Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

Zhang Ming, Email: zhangmingscu@126.com

Keywords：

Retinoblastoma; Disease attributes; Chemotherapy, cancer, regional perfusion; Laser coagulation; Cryotherapy

DOI：

10.3760/cma.j.issn.1005-1015.2020.01.010

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe the clinical characteristics of retinoblastoma (RB) in Southwest China.Methods A retrospective clinical study. From January 2010 to December 2017, 66 RB patients diagnosed in Ophthalmology Department of West China Hospital of Sichuan University were included in the study. All the patients underwent ocular B-ultrasound, orbital CT or MRI examination. Ten patients underwent RetCam examination at the same time. Twenty-nine patients were diagnosed by histopathological examination, and 37 patients were diagnosed by clinical symptoms and imaging examination. According to whether the tumor invaded the orbit and optic nerve, it could be divided into extraocular stage and intraocular stage. Intraocular tumors were divided into A-E stages according to the international intraocular RB classification. Treatments were performed according to different stages. The general information, age at diagnosis, course of diseases (the time between onset symptoms and diagnosis), causes of visiting a doctor, classification, treatment methods and eyeball preservation rate were retrospectively analyzed.Results Patients all came from Southwest China (56 patients from Sichuan Province, 2 patients from Yunnan Province, 2 patients from Guizhou Province, and 6 patients from Tibet). The permanent residence were identified in 43 patients, including 27 patients (62.8%) from rural areas. There were 38 males (57.6%); 50 unilateral tumors (75.8%) and 16 bilateral tumors (24.2%); 51 first-visiting patients (77.3%) and 15 re-visiting patients (22.7%). The average diagnostic age of first-visiting patients was 20.9±14.4 months, with 23.2±14.7 and 11.2±7.6 months for unilateral and bilateral tumors, respectively. There were 41 patients had definite course and causes, of whom the average course was 90.6±115.2 days. The most common cause was leucocoria in 32 patients (62.7%), followed by redness and swelling in 4 patients (9.8%), and other causes in 5 patients (12.2%). Among the 15 re-visiting patients, the average diagnostic age was 63.6±46.8 months, the average course was 32.8±45.5 months. Recurrence was occurred in 5 patients (33.3%), leucocoria in 4 patients (26.7%), postoperative complication in 3 patients (20.0%), protrusion in 2 patients (13.3%) and redness in 1 (6.7%) patient, respectively. Fifty out of 82 eyes were admitted to hospital, including 37 eyes of first-visiting patients and 13 eyes of re-visiting patients. Among 37 first-visiting eyes, there were 5 eyes (13.5%) in stage A-C, 26 eyes (70.3%) in stage D-E, 6 eyes (16.2%) in extraocular stage. Five eyes in stage A-C were treated with laser photocoagulation and (or) cryotherapy combined with systemic chemotherapy. Four eyes in stage D were treated with intraocular arterial chemotherapy. Nineteen eyes (51.3%) were performed with enucleation, 2 eyes (5.4%) with evisceration and 7 eyes (18.9%) abandoned treatment. Among 13 re-visiting eyes, 6 eyes (46.2%, with 5 eyes of recurrence) had been enucleated before, 4 eyes (30.8%) were in extraocular stage and 3 eyes (23.1%) in stage D-E. Five eyes (38.5%) were treated with evisceration, 4 eyes (30.8%) with enucleation, 1 eye with oculoplastic surgery and 3 eyes (23.1%) abandoned treatment. The rate of eye preservation was 18.0%, 29.0% for intraocular stage and 0% for extraocular stage, respectively.Conclusion RB patients in Southwest China have a longer course between onset symptoms and diagnosis, more advanced classification and lower rate of eye preservation.

Citation： Zhou Sirui, Min Xiaoxue, Tao Yunhan, Mu Jia, Gou Yueqin, Tao Mengying, Zhang Ming. Clinical analysis of 66 patients of retinoblastoma. Chinese Journal of Ocular Fundus Diseases, 2020, 36(1): 42-45. doi: 10.3760/cma.j.issn.1005-1015.2020.01.010 Copy

1.	Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma[J]. Lancet, 2012, 379(9824): 1436-1446. DOI: 10.1016/S0140-6736(11)61137-9.
2.	Rodriguez-Galindo C, Wilson MW. Retinoblastoma[J]. Pediatr Clin North Am, 2015, 62(1): 201-223. DOI: 10.1016/j.pcl.2014.09.014.
3.	程湧, 杨斐, 赵敏, 等. 眼外期视网膜母细胞瘤临床特点和生存率分析[J]. 中华眼底病杂志, 2015, 31(5): 447-450. DOI: 10.3760/cma.j.issn.1005-1015.2015.05.009.Cheng Y, Yang F, Zhao M, et al. The clinical characteristics and survival rate of the patients with extraocular retinoblastoma[J]. Chin J Ocul Fundus Dis, 2015, 31(5): 447-450. DOI: 10.3760/cma.j.issn.1005-1015.2015.05.009.
4.	Bosaleh A, Sampor C, Solernou V, et a1. Outcomeof childrenwith retinoblastoma and isolated choroidal invasion[J]. Arch Ophthalmol, 2012, 130(6): 724-729. DOI: 10.1001/archophthalmol.2012.567.
5.	Chantada GI, Qaddoumi I, Canturk S, et a1. Strategies to manage retinoblastoma in developing countries[J]. Pediatr Blood Cancer, 2011, 56(3): 341-348. DOI: 10.1002/pbc.22843.
6.	Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma[J]. Curr Opin Ophthalmol, 2006, 17(3): 228-234. DOI: 10.1097/01.icu.0000193079.55240.18.
7.	Zhao J, Li S, Shi J, et al. Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China[J]. Br J Ophthalmol, 2011, 95(10): 1372-1375. DOI: 10.1136/bjo.2010.191130.
8.	Chung SE, Sa HS, Koo HH, et al. Clinical manifestations and treatment of retinoblastoma in Korea[J]. Br J Ophthalmol, 2008, 92(9): 1180-1184. DOI: 10.1136/bjo.2008.140046.
9.	Mallipatna AC, Sutherland JE, Gallie BL, et al. Management and outcome of unilateral retinoblastoma[J]. J AAPOS, 2009, 13(6): 546-550. DOI: 10.1016/j.jaapos.2009.09.004.
10.	Singh G, Daniels AB. Disparities in retinoblastoma presentation, treatment, and outcomes in developed and less-developed countries[J]. Semin Ophthalmol, 2016, 31(4): 310-316. DOI: 10.3109/08820538.2016.1154177.
11.	Bai S, Ren R, Li B, et al. Delay in the diagnosis of retinoblastoma in China[J]. Acta Ophthalmol, 2011, 89(1): 72-74. DOI: 10.1111/j.1755-3768.2010.01930.x.
12.	Abramson DH, Shields CL, Munier FL, et al. Treatment of retinoblastoma in 2015: agreement and disagreement[J]. JAMA Ophthalmol, 2015, 133(11): 1341-1347. DOI: 10.1001/jamaophthalmol.2015.3108.
13.	American Brachytherapy Society - Ophthalmic Oncology Task Force, ABS - OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma[J]. Brachytherapy, 2014, 13(1): 1-14. DOI: 10.1016/j.brachy.2013.11.008.

1. Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma[J]. Lancet, 2012, 379(9824): 1436-1446. DOI: 10.1016/S0140-6736(11)61137-9.
2. Rodriguez-Galindo C, Wilson MW. Retinoblastoma[J]. Pediatr Clin North Am, 2015, 62(1): 201-223. DOI: 10.1016/j.pcl.2014.09.014.
3. 程湧, 杨斐, 赵敏, 等. 眼外期视网膜母细胞瘤临床特点和生存率分析[J]. 中华眼底病杂志, 2015, 31(5): 447-450. DOI: 10.3760/cma.j.issn.1005-1015.2015.05.009.Cheng Y, Yang F, Zhao M, et al. The clinical characteristics and survival rate of the patients with extraocular retinoblastoma[J]. Chin J Ocul Fundus Dis, 2015, 31(5): 447-450. DOI: 10.3760/cma.j.issn.1005-1015.2015.05.009.
4. Bosaleh A, Sampor C, Solernou V, et a1. Outcomeof childrenwith retinoblastoma and isolated choroidal invasion[J]. Arch Ophthalmol, 2012, 130(6): 724-729. DOI: 10.1001/archophthalmol.2012.567.
5. Chantada GI, Qaddoumi I, Canturk S, et a1. Strategies to manage retinoblastoma in developing countries[J]. Pediatr Blood Cancer, 2011, 56(3): 341-348. DOI: 10.1002/pbc.22843.
6. Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma[J]. Curr Opin Ophthalmol, 2006, 17(3): 228-234. DOI: 10.1097/01.icu.0000193079.55240.18.
7. Zhao J, Li S, Shi J, et al. Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China[J]. Br J Ophthalmol, 2011, 95(10): 1372-1375. DOI: 10.1136/bjo.2010.191130.
8. Chung SE, Sa HS, Koo HH, et al. Clinical manifestations and treatment of retinoblastoma in Korea[J]. Br J Ophthalmol, 2008, 92(9): 1180-1184. DOI: 10.1136/bjo.2008.140046.
9. Mallipatna AC, Sutherland JE, Gallie BL, et al. Management and outcome of unilateral retinoblastoma[J]. J AAPOS, 2009, 13(6): 546-550. DOI: 10.1016/j.jaapos.2009.09.004.
10. Singh G, Daniels AB. Disparities in retinoblastoma presentation, treatment, and outcomes in developed and less-developed countries[J]. Semin Ophthalmol, 2016, 31(4): 310-316. DOI: 10.3109/08820538.2016.1154177.
11. Bai S, Ren R, Li B, et al. Delay in the diagnosis of retinoblastoma in China[J]. Acta Ophthalmol, 2011, 89(1): 72-74. DOI: 10.1111/j.1755-3768.2010.01930.x.
12. Abramson DH, Shields CL, Munier FL, et al. Treatment of retinoblastoma in 2015: agreement and disagreement[J]. JAMA Ophthalmol, 2015, 133(11): 1341-1347. DOI: 10.1001/jamaophthalmol.2015.3108.
13. American Brachytherapy Society - Ophthalmic Oncology Task Force, ABS - OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma[J]. Brachytherapy, 2014, 13(1): 1-14. DOI: 10.1016/j.brachy.2013.11.008.

Chinese Journal of Ocular Fundus Diseases

Clinical analysis of 66 patients of retinoblastoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content